Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $62.67 –$84.29 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Alnylam currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Alnylam Pharmaceuticals, Inc. Price
Investors interested in the Medical - Biomedical and Genetics industry may consider Genomic Health, Inc. (GHDX - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ALNY going up? Or down? Predict to see what others think:Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>